Food and Drug Administration officials on Tuesday added a bleeding risk to fact sheets for Johnson & Johnson’s COVID-19 vaccine. Healthcare providers administering the vaccine and recipients and caregivers are now being told that there’s a safety signal for immune thrombocytopenia, a disorder stemming from low platelet levels that can cause excessive bleeding. “Reports of adverse events following use of the Janssen COVID-19 Vaccine under emergency use authorization suggest an increased risk of immune thrombocytopenia (ITP) during the 42 days following vaccination,” the regulator tells administrators (pdf). “The chance of having this occur is very low,” it said in the sheet (pdf) for recipients and caregivers. People who have been diagnosed with ITP before should discuss with their healthcare provider the risk of the condition from vaccination and a potential need to monitor platelets if they move forward with getting the vaccine. Janssen is a subsidiary of Johnson & Johnson (J&J). …